Saturna Capital Corp Makes New Investment in Dynavax Technologies Co. (NASDAQ:DVAX)

Saturna Capital Corp acquired a new position in Dynavax Technologies Co. (NASDAQ:DVAX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,613 shares of the biopharmaceutical company’s stock, valued at approximately $174,000.

A number of other large investors have also added to or reduced their stakes in DVAX. US Bancorp DE increased its stake in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC increased its stake in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Dynavax Technologies in the 4th quarter worth approximately $71,000. Finally, Nisa Investment Advisors LLC increased its stake in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $13.74 on Thursday. The company has a market cap of $1.70 billion, a P/E ratio of 76.33 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The business’s 50 day moving average price is $13.08 and its 200-day moving average price is $12.27. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their target price for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.